These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. De Roeck L; Michaux L; Debackere K; Lierman E; Vandenberghe P; Devos T Hematology; 2018 Dec; 23(10):785-792. PubMed ID: 29993347 [TBL] [Abstract][Full Text] [Related]
7. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Kubesova B; Pavlova S; Malcikova J; Kabathova J; Radova L; Tom N; Tichy B; Plevova K; Kantorova B; Fiedorova K; Slavikova M; Bystry V; Kissova J; Gisslinger B; Gisslinger H; Penka M; Mayer J; Kralovics R; Pospisilova S; Doubek M Leukemia; 2018 Feb; 32(2):450-461. PubMed ID: 28744014 [TBL] [Abstract][Full Text] [Related]
8. [The relationship between symptom burden and hematologic responses after treatment with interferon/hydroxyurea in patients with polycythemia vera]. Liu D; Xu ZF; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):635-641. PubMed ID: 34547868 [No Abstract] [Full Text] [Related]
9. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773 [TBL] [Abstract][Full Text] [Related]
11. Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. Kjær L; Cordua S; Holmström MO; Thomassen M; Kruse TA; Pallisgaard N; Larsen TS; de Stricker K; Skov V; Hasselbalch HC PLoS One; 2016; 11(10):e0165336. PubMed ID: 27764253 [TBL] [Abstract][Full Text] [Related]
12. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873 [TBL] [Abstract][Full Text] [Related]
13. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541 [TBL] [Abstract][Full Text] [Related]
14. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184 [TBL] [Abstract][Full Text] [Related]
15. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
16. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Larsen TS; Pallisgaard N; de Stricker K; Møller MB; Hasselbalch HC Hematology; 2009 Feb; 14(1):11-5. PubMed ID: 19154659 [TBL] [Abstract][Full Text] [Related]
17. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms. Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012 [TBL] [Abstract][Full Text] [Related]
18. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. Hansen IO; Sørensen AL; Hasselbalch HC Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124 [TBL] [Abstract][Full Text] [Related]
19. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Czech J; Cordua S; Weinbergerova B; Baumeister J; Crepcia A; Han L; Maié T; Costa IG; Denecke B; Maurer A; Schubert C; Feldberg K; Gezer D; Brümmendorf TH; Müller-Newen G; Mayer J; Racil Z; Kubesova B; Knudsen T; Sørensen AL; Holmström M; Kjær L; Skov V; Larsen TS; Hasselbalch HC; Chatain N; Koschmieder S Leukemia; 2019 Apr; 33(4):995-1010. PubMed ID: 30470838 [TBL] [Abstract][Full Text] [Related]
20. Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. Lindgren M; Samuelsson J; Nilsson L; Knutsen H; Ghanima W; Westin J; Johansson PL; Andréasson B Eur J Haematol; 2018 May; 100(5):419-425. PubMed ID: 29369421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]